Does Tirzepatide / Semaglutide Cause Depression? FDA Postmarket Surveillance + Evidence Review

What the FDA labels said: the historical suicidality warning

From approximately 2021 through early 2026, three GLP-1 receptor agonist labels approved for weight management carried a precautionary statement in Section 5 (Warnings and Precautions) titled “Suicidal Behavior and Ideation.” The warning arose after the FDA received FAERS (Adverse Event Reporting System) reports of suicidal ideation and self-injury among patients on weight-management GLP-1s, which prompted initial regulatory action in the same window as the EMA's July 2023 referral (triggered by Iceland flagging a small cluster of post-marketing cases).

The language across the three weight-management labels was substantively similar. The Wegovy prescribing information (DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b) previously stated in Section 5 verbatim:

“Suicidal behavior and ideation, including completed suicides, have been reported in clinical trials and postmarketing use of other weight management products. Monitor patients for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue WEGOVY in patients who experience suicidal thoughts or behaviors.”

Source: WEGOVY US Prescribing Information, Section 5 Warnings and Precautions — historical text (Suicidal Behavior and Ideation subsection), DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b. This subsection was removed effective 02/2026 per FDA Drug Safety Communication January 13, 2026.

The Zepbound label (DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b) carried a parallel Section 5 warning:

“Suicidal behavior and ideation, including completed suicides, have been reported in clinical trials and postmarketing use of other weight management products. Monitor patients for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue ZEPBOUND in patients who experience suicidal thoughts or behaviors.”

Source: ZEPBOUND US Prescribing Information, Section 5 Warnings and Precautions — historical text (Suicidal Behavior and Ideation subsection), DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b. Removed effective 02/2026.

The Saxenda label (liraglutide 3 mg, DailyMed SetID 3946d389-0926-4f77-a708-0acb8153b143) carried the same warning in Section 5.9, and Foundayo (orforglipron, SetID 8ac446c5-feba-474f-a103-23facb9b5c62), approved in April 2026, was approved after the warning was already removed and therefore never carried this subsection at all.

Three important framings for patients reading 2024-2025 articles online that still quote this language:

1. This was a Section 5 precautionary warning — not a boxed warning. The two are different regulatory tiers. A boxed (black box) warning is the most serious FDA warning category. GLP-1s never had a boxed warning for suicidality. Contrave (naltrexone + bupropion) carries a boxed warning for suicidal thoughts and behaviors in patients under 25 — a class effect of bupropion as an antidepressant. These are not equivalent and should not be equated.
2. The warning text explicitly referenced “other weight management products” — meaning weight-loss drugs with a pre-existing suicidality signal (primarily topiramate and the lorcaserin era), not GLP-1s per se. The FDA was applying a precautionary class approach to the weight-management category pending its own longitudinal GLP-1 data.
3. The warning has been removed. As of February 2026, the “Recent Major Changes” block at the top of each label on DailyMed reads “Suicidal Behavior and Ideation … (Removed) 02/2026.”

The 2023-2026 FDA and EMA postmarket surveillance investigation

The formal regulatory investigation unfolded in three stages across roughly two and a half years.

Stage 1: EMA referral, July 2023

In July 2023, the European Medicines Agency opened a formal review of GLP-1 receptor agonists — including dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide — after Iceland reported a small number of cases of suicidal thoughts and self-injury in post-marketing use. The review was conducted under EMA Article 20 referral procedures, meaning it was a formal pharmacovigilance concern triggering mandatory evidence collection from all EU member states, manufacturers, and published literature. Tirzepatide (Mounjaro / Zepbound) was added to the scope after the original referral.

The EMA Pharmacovigilance Risk Assessment Committee (PRAC) spent nine months reviewing clinical trial data, EudraVigilance spontaneous reports, post-marketing surveillance from multiple countries, and published epidemiologic studies. On April 12, 2024, the PRAC published its conclusions verbatim:

“the available evidence does not support a causal association between the Glucagon-Like Peptide-1 receptor agonists (GLP-1) — dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide — and suicidal and self-injurious thoughts and actions.”

Source: EMA PRAC Meeting Highlights, 8-11 April 2024. EMA.europa.eu. Verified 2026-05-10.

The PRAC concluded no update to product information was warranted. This was the first major regulatory body to conclude the investigation.

Stage 2: FDA FAERS surveillance, 2023-2025

In parallel, the FDA reviewed its own Adverse Event Reporting System (FAERS) data for semaglutide and tirzepatide. FAERS is a passive spontaneous-reporting database — meaning it captures reports submitted voluntarily by patients, caregivers, and health professionals, not from controlled clinical trials. FAERS data can identify signals, but spontaneous reporting rates are highly sensitive to media coverage, regulatory announcements, and stimulated reporting cycles. The raw FAERS count of suicidal ideation reports for semaglutide did increase in 2023 as public awareness of the question grew — but an increase in reporting is not an increase in incidence.

McIntyre and colleagues (Expert Opin Drug Saf 2024, PMID 38087976) published a Bradford-Hill analysis of the FAERS data — applying the nine canonical epidemiologic criteria for establishing causation (strength, consistency, specificity, temporality, biological gradient, plausibility, coherence, experiment, analogy) — and concluded:

“Using the Bradford Hill criteria, however, and taking into consideration confounders, no causal link between GLP-1 RAs and suicidality exists.”

Source: McIntyre RS, et al. Expert Opin Drug Saf. 2024. PMID 38087976. Verified 2026-05-10.

Stage 3: FDA Drug Safety Communication, January 2026

On January 13, 2026, the FDA issued a Drug Safety Communication titled “FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Labeling.” The DSC announced the FDA had reviewed 91 placebo-controlled clinical trials covering 107,910 patients — 60,338 on a GLP-1 RA (semaglutide, liraglutide, tirzepatide, dulaglutide, exenatide, lixisenatide) and 47,572 on placebo — across weight-management and diabetes indications. The conclusion: the data did not identify an increased risk of suicidal ideation or behavior, or of related psychiatric adverse events including anxiety, depression, irritability, or psychosis. The FDA formally requested manufacturers remove the suicidal-behavior-and-ideation §5 subsection from Wegovy, Saxenda, and Zepbound labels.

As of February 2026, all three labels on DailyMed were updated accordingly. The diabetes-only labels — Ozempic (semaglutide), Mounjaro (tirzepatide), Trulicity (dulaglutide), Victoza (liraglutide 1.2/1.8 mg), Rybelsus (oral semaglutide), Byetta, Bydureon, and Adlyxin — never carried this specific subsection because the original signal had emerged from weight-management indications.

What clinical trials actually show about depression

The strongest primary-source evidence on GLP-1 mood effects in the weight-management context comes from four publications. None are from the Reddit-driven anecdote layer; all are PubMed-indexed peer-reviewed studies.

Wadden et al., STEP 1/2/3/5 post-hoc — PHQ-9 depression data

Wadden and colleagues (JAMA Intern Med 2024, PMID 39226070) pooled 3,377 participants from STEP 1/2/3 and 304 from STEP 5 — all randomized, all assessed with the validated Patient Health Questionnaire-9 (PHQ-9) for depression and the Columbia-Suicide Severity Rating Scale (C-SSRS) for suicidal ideation. The PHQ-9 is a nine-item validated instrument scored 0-27; a difference of 0.5 points is generally considered the minimum clinically important difference.

The depression finding was directionally favorable for semaglutide:

“Semaglutide 2.4 mg resulted in significantly greater reductions in PHQ-9 total score vs. placebo from baseline to week 68 [mean ±SD PHQ-9 score: semaglutide 2.0 ±2.9 vs. placebo 2.4 ±3.3; treatment difference −0.56 (95% CI −0.73 to −0.39); P < .001].”

Source: Wadden TA et al. JAMA Intern Med. 2024. PMID 39226070. Verified 2026-05-10.

On suicidality specifically, the post-hoc found:

“1% or fewer of participants reported suicidal ideation/behavior during treatment, with no differences between semaglutide, 2.4 mg, and placebo.”

Source: Wadden TA et al. JAMA Intern Med. 2024. PMID 39226070. Verified 2026-05-10.

The critical caveat: the STEP trials excluded participants with current major depression, serious mental illness, or prior suicide attempt. The PHQ-9 improvement does not necessarily generalize to patients with pre-existing moderate-to-severe depression.

Wang et al., TriNetX cohort — incident suicidal ideation

Wang and colleagues (Nature Medicine 2024, PMID 38182782) used the TriNetX research network to compare incident suicidal ideation between 240,618 overweight/obese adults newly prescribed semaglutide versus adults newly prescribed a non-GLP-1 comparator, using propensity-score matching. Results:

• Incident suicidal ideation, overweight/obesity cohort: HR 0.27 (95% CI 0.20-0.36) — substantially lower risk in the semaglutide group
• Recurrent suicidal ideation: HR 0.44 (95% CI 0.32-0.60)

“Our findings do not support higher risks of suicidal ideation with semaglutide compared with non-GLP1R agonist anti-obesity or anti-diabetes medications.”

Source: Wang W et al. Nat Med. 2024. PMID 38182782. Verified 2026-05-10.

Ueda et al., Sweden + Denmark registry — depression and suicide death

Ueda and colleagues (JAMA Intern Med 2024, PMID 39226030) used nationwide health registries from Sweden and Denmark (2013-2021) to compare adults with T2D initiating a GLP-1 RA versus adults initiating an SGLT2 inhibitor — an active comparator design that controls for the channeling bias inherent in comparing GLP-1 users to non-users. Primary outcomes covering both suicide and depression:

• Suicide death: HR 1.25 (95% CI 0.83-1.88) — confidence interval crosses 1.0; the comparison is not statistically significant
• Self-harm hospitalization: not significant
• Incident depression and anxiety-related disorders: not significant

“use of GLP-1 receptor agonists compared with SGLT2 inhibitors was not associated with an increased risk of suicide death, self-harm, or incident depression and anxiety-related disorders.”

Source: Ueda P et al. JAMA Intern Med. 2024. PMID 39226030. Verified 2026-05-10.

SELECT trial — 17,604-patient psychiatric safety dataset

SELECT (PMID 37952131), the largest semaglutide trial published to date, randomized 17,604 adults with overweight/obesity and established cardiovascular disease to semaglutide 2.4 mg vs. placebo over a mean of 39.8 months. Serious psychiatric adverse events were not more frequent in the semaglutide arm than placebo across the trial's extensive safety reporting. SELECT alone contributes nearly 18,000 patients to the FDA's 107,910-patient pooled denominator.

Mechanism considerations: GLP-1 receptors in the brain

GLP-1 receptors are present in the central nervous system, including regions directly involved in mood regulation and reward signaling: the hypothalamus, the ventral tegmental area (VTA), the nucleus accumbens, the prefrontal cortex, and the hippocampus. This anatomical distribution provides a biologically plausible pathway by which a GLP-1 RA could, in principle, modulate mood and reward processing — including food reward, social reward, and affect.

Biological plausibility is not the same as clinical demonstration. The published population-level evidence (see Section 3 above) does not translate the CNS receptor distribution into a measurable increase in depression or suicidality at the population level. What the mechanism does support:

• Appetite suppression — a core and intended drug effect — acts partly through hypothalamic GLP-1 receptor signaling that suppresses both hunger and hedonic eating. Patients who previously derived strong pleasure from food may experience the diminished food reward as a felt-sense change.
• Possible broader reward modulation — rodent studies have suggested GLP-1 receptor agonism modulates dopamine release in the nucleus accumbens, affecting both food and non-food reward. Whether this translates to clinically meaningful mood effects in humans at therapeutic doses has not been established in prospective trials.
• Preclinical neuroprotective signals — separate from depression risk, some animal and human observational data suggest GLP-1 receptor agonists may have neuroprotective properties (being studied in Alzheimer's and Parkinson's disease contexts). These are investigational and not established.

The honest framing: GLP-1 RA effects on CNS mood circuitry are biologically plausible and scientifically active. The current primary-source population evidence — four large studies plus the FDA and EMA reviews — does not support a causal increase in depression or suicidality. This is a live research area; the published evidence as of May 2026 should be stated as it stands, not inflated toward either alarm or dismissal.

Depression vs. anhedonia: two related but distinct phenomena

Patient reports on GLP-1s frequently conflate two clinically distinct phenomena: clinical depression and anhedonia. Understanding the distinction matters for how a prescriber should respond.

Clinical depression (major depressive disorder) is defined by the DSM-5 as a depressed mood or loss of interest most of the day, nearly every day, for at least two weeks, plus at least four additional symptoms from a defined list (changes in sleep, energy, concentration, appetite, psychomotor activity, worthlessness, or suicidal ideation) causing significant functional impairment. Depression is a diagnosis requiring clinical evaluation — it is not defined by a single symptom or a feeling of being “flat.”

Anhedonia — specifically the “loss of food joy,” “flatness,” or “food noise gone” phenomenon — is a different (though overlapping) patient experience on GLP-1s. GLP-1 receptor signaling in the mesolimbic reward circuit (VTA → nucleus accumbens) is part of the mechanism by which these drugs suppress hedonic eating. Patients who previously derived strong reward from eating may experience the reduction of that reward as a real felt-sense change that they describe as “flat” or “emotionally blunted.” That experience is not the same as a clinical depressive episode, though it can be distressing and warrants clinical attention if persistent.

The companion article on this site covers the anhedonia and emotional blunting evidence in depth — including what the published literature supports (and does not support), what the current labels say, and what to do if you experience it:

Who should be especially cautious: higher-risk populations

The clinical-trial evidence on GLP-1 mood safety was built in populations from which high-risk patients were deliberately excluded. The following groups were generally excluded from STEP and SURMOUNT and should receive more careful prescriber assessment before starting and closer monitoring during titration:

Standard clinical practice prior to GLP-1 initiation in any patient with a psychiatric history includes PHQ-9 screening (a validated nine-item depression questionnaire, available free at phqscreeners.com), discussion of psychiatric history and current medications, and agreement on a monitoring plan for the first 8-12 weeks of titration.

Warning signs to act on immediately

The prior FDA label language for Wegovy, Saxenda, and Zepbound instructed prescribers to “monitor patients for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior” — and while that subsection has been removed from the label, the clinical standard of care for monitoring these symptoms remains appropriate, particularly in higher-risk patients.

What to do if you experience mood changes on a GLP-1

1. Track it concretely before calling. Note the date of onset, what specifically changed (sleep quality, energy level, interest in activities, food motivation, social engagement), severity on a 1-10 scale, and whether it correlates with dose escalation. A PHQ-9 self-screen (free at phqscreeners.com) takes two minutes and gives a structured score to hand to a clinician rather than a subjective description.
2. Contact your prescriber — not just Reddit. Mood symptoms on a GLP-1 are a clinical conversation. Even with the suicidality warning removed, prescribers should evaluate, consider dose adjustment, or refer to mental health care based on lived experience — particularly for patients with any psychiatric history.
3. Do not self-discontinue without medical guidance. Abruptly stopping a GLP-1 RA after weeks or months of appetite suppression can produce a rapid return of food preoccupation, hunger surges, and weight regain — all of which can themselves destabilize mood. The tapering or discontinuation decision belongs with your prescriber. If mood symptoms are severe or urgent, call 988 first and discuss discontinuation with your clinician as a non-emergent next step.
4. Discuss whether the dose, timing, or agent is right for you. Some patients report that dose reduction reduces mood-related symptoms while preserving partial weight-loss benefit. Dose-spacing (every-other-week instead of weekly) is another option explored in some clinical practices. Switching from semaglutide to tirzepatide (or vice versa) may alter the pharmacological profile. These are clinical decisions — your prescriber can map out the tradeoffs.
5. Consider a referral to a behavioral health provider. GLP-1s do not operate in a psychological vacuum. Rapid weight loss involves significant body-image adjustment, relationship changes, and sometimes an unexpected renegotiation of identity and habits. A therapist familiar with weight and health psychology can be a valuable co-treatment alongside your prescriber.

Compounded semaglutide and tirzepatide: same mood profile

Compounded semaglutide from a licensed 503A pharmacy contains the same active molecule — semaglutide — as Wegovy and Ozempic. Compounded tirzepatide contains the same active molecule as Zepbound and Mounjaro. The mood effects of a GLP-1 receptor agonist are pharmacological — driven by GLP-1 receptor binding in the CNS — not a product of the specific brand, formulation, or manufacturer. Patients on compounded GLP-1s should apply the same monitoring approach: track mood changes, use the PHQ-9 as a screening tool, discuss with their prescriber, and use 988 if in crisis.

One additional caution: compounded products do not go through the same FDA-reviewed clinical trial process as brand-name drugs. Excipients, pH adjusters, and reconstitution solvents in compounded versions may differ across pharmacies and have not been studied for CNS effects. This is a separate source of uncertainty from the branded-drug evidence summarized above.

Related research

• GLP-1s and mental health: anhedonia, emotional blunting, and the FDA's January 2026 suicidality warning removal — companion deep-dive covering the anhedonia, loss-of-food-joy, and emotional-blunting patient reports; eating-disorder organization guidance; and what current labels say post-February 2026.
• GLP-1 side-effect questions answered (master Q&A hub) — complete coverage of every common GLP-1 side effect from FDA labels and trial data, including the EMA suicidality review context.
• Why does tirzepatide / semaglutide make you tired? GLP-1 fatigue: onset, mechanism, and management — companion side-effect deep-dive covering the five biological mechanisms behind GLP-1 fatigue; relevant because fatigue and low energy can mimic or compound mood symptoms.
• Why does tirzepatide cause headaches? Frequency, mechanism, and when to call your doctor — titration-phase side-effect companion; headache cluster often accompanies the early titration period where mood monitoring is most relevant.
• Antidepressants, weight, and GLP-1 receptor agonists — evidence review of drug-interaction landscape: SSRI/SNRI weight-gain literature, bupropion considerations, and who needs the most careful monitoring.
• SSRI + GLP-1: drug interactions, weight effects, and combined use evidence — verbatim Section 7 review of all six GLP-1 labels confirms no SSRI interaction; SSRI-by-SSRI weight profile comparison; Contrave CYP2D6 interaction explained; how the February 2026 FDA suicidality-warning removal applies to patients already on an antidepressant.
• Wellbutrin XL for weight loss: how fast and how much? — covers Contrave's boxed warning for suicidal thoughts and behaviors (bupropion class) and how it differs from the historical GLP-1 Section 5 warning.
• GLP-1 medications pillar — every approved and investigational agent

Important disclaimer. This article is educational and does not constitute medical advice. The information above is a plain-language summary of FDA-approved prescribing information, regulatory communications, and published clinical trial data. Every clinical claim is sourced from the verbatim DailyMed FDA labels for the listed drugs, from the FDA Drug Safety Communication (January 13, 2026), from the EMA PRAC April 2024 meeting highlights, or from PubMed-indexed primary-source publications cited in the References section. The choice of whether to start, stop, or modify a GLP-1 medication — including decisions about mood monitoring and psychiatric co-treatment — must be made with a licensed prescriber who knows your full medical history, psychiatric history, comorbidities, and medications. If you are experiencing thoughts of self-harm or suicide, call or text 988 immediately. Weight Loss Rankings does not provide medical advice, diagnosis, or treatment.